CDC Advisory Committee Recommends Preferential Use of Live Attenuated Influenza Vaccine (LAIV) for Eligible Children 2 to 8 Years of Age

June 26, 2014 The MedImmune Specialty Care division of AstraZeneca announced that the U.S. Centers for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that when available, Live Attenuated Influenza Vaccine (LAIV) should be used for healthy children 2 to 8 years of age, who have no contraindications or precautions. The ACIP’s unanimous vote was based on …